儿童代谢功能障碍相关脂肪性肝病对标准治疗的纵向应答:改善与恶化率及相关因素
本研究利用两项大型随机对照试验数据,基于丙氨酸氨基转移酶、γ-谷氨酰转移酶和肝组织学变化定义儿童代谢功能障碍相关脂肪性肝病的复合改善与恶化标准,并应用于440例患儿。标准治疗1年后22%改善、2年后31%改善,但1年和2年后均有20%恶化;体质量指数z评分和胆固醇变化与改善或恶化最相关。
要点
- 标准治疗1年后22%、2年后31%的患儿达到复合改善标准。
- 标准治疗1年和2年后均有20%的患儿出现复合恶化。
- 体质量指数z评分和胆固醇的变化与改善或恶化最相关。
核心结论
- 标准治疗下超过四分之一患儿可能改善,而五分之一患儿可能恶化;针对体质量指数和脂质参数的干预可能有助于随时间改善代谢功能障碍相关脂肪性肝病。
研究设计与样本
- 利用两项大型随机对照试验的数据,基于丙氨酸氨基转移酶、γ-谷氨酰转移酶和肝组织学变化推导复合改善与恶化定义,并应用于440例代谢功能障碍相关脂肪性肝病患儿。
主要发现
- 标准治疗1年后22%的患儿显示改善,2年后增至31%。
- 标准治疗1年和2年后均有20%的患儿显示恶化。
- 采用逐步模型选择的逻辑回归分析显示,体质量指数z评分和胆固醇的变化与改善或恶化最相关。
关键数值与推荐
- 改善定义为丙氨酸氨基转移酶下降≥40%且γ-谷氨酰转移酶下降≥20%。
- 恶化定义为丙氨酸氨基转移酶和γ-谷氨酰转移酶均升高≥20%。
临床怎么用
- 作者认为,针对影响体质量指数和脂质参数的干预可能有助于随时间改善代谢功能障碍相关脂肪性肝病。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Longitudinal outcomes in children with metabolic dysfunction-associated steatotic liver disease (MASLD) remain unclear due to the absence of a standardized monitoring approach. This study aimed to (1) define improvement and worsening in children with MASLD, (2) estimate rates of improvement or deterioration with the standard of care (SOC) over 1 and 2 years, and (3) identify baseline and longitudinal factors associated with improvement or worsening. APPROACH AND RESULTS: Using data from 2 large randomized controlled trials, we derived definitions for composite improvement and worsening of MASLD based on associations between changes in ALT, GGT, and liver histology after 1 and 2 years. Improvement was defined as ≥40% decrease in ALT and ≥20% decrease in GGT and worsening as ≥20% increase in both ALT and GGT. We applied definitions to a cohort of 440 children with MASLD. After 1 year of SOC, 22% of children with MASLD showed improvement, increasing to 31% after 2 years. However, 20% showed worsening after both 1 and 2 years despite receiving SOC. Logistic regression analysis, employing stepwise model selection, identified changes in body mass index z-score and cholesterol to be most associated with improvement or deterioration. CONCLUSIONS: This study developed criteria for improvement and worsening in children with MASLD over 1 and 2 years of follow-up. With SOC, over one-quarter of children are likely to improve while one-fifth of children are likely to worsen. Targeting interventions that affect body mass index and lipid parameters may help improve MASLD over time.
引用
- Newton KP, Jayasekera D, Blackford AL, et al. Longitudinal response to standard of care in pediatric metabolic dysfunction-associated steatotic liver disease: Rates of improvement and worsening, and factors associated with outcomes. Hepatology. 2025. PMID: 39773889. doi:10.1097/HEP.0000000000001216
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。